Why PolyNovo and these ASX healthcare shares could be long term market beaters

PolyNovo Ltd (ASX:PNV) and these ASX healthcare shares could be long term markets beaters for Australian investors. Here's why…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I think the healthcare sector is a great place to invest with a long term view due to the favourable tailwinds that it is experiencing.

These include ageing populations around the globe, increased chronic disease burden, and better technologies. But with so many options for investors to choose from, which ones should you be buying?

Below are three ASX healthcare shares I believe could provide stellar returns for investors over the long term:

Nanosonics Ltd (ASX: NAN)

The first healthcare share to consider buying is Nanosonics. It is an infection prevention specialist best known for its trophon EPR disinfection system for ultrasound probes. It is also the first high level disinfection system for ultrasound probes that is effective against high-risk, cancer causing strains of Human Papilloma Virus. This has gone down very well with healthcare institutions, leading to its installed base growing at a rapid rate over the last few years. The good news is that there's still a large addressable market for it to grow into in the coming years. This should be supported by the launch of new products targeting unmet needs which have similar market opportunities. If they are anywhere near as successful, Nanosonics will have a very bright future ahead of it.

PolyNovo Ltd (ASX: PNV)

Another healthcare share which I think could have a bright future ahead of it is PolyNovo. It is the medical device company behind the NovoSorb Biodegradable Temporising Matrix (BTM) product. This synthetic polymer was developed at CSIRO and is used by clinicians to treat serious burn and skin trauma patients. It can be used in surgical procedures and will eventually biodegrade safely and be excreted by the body. The company's current target market has a sizeable $1.5 billion addressable opportunity. However, management is looking to expand BTM's use into the hernia and breast treatment markets. This would lift its addressable market to a total of $7.5 billion if successful.

Ramsay Health Care Limited (ASX: RHC)

A final healthcare share to look at is Ramsay Health Care. This global private hospital operator currently has 480 facilities across 11 countries. Although the near future is not going to be easy for Ramsay due to both the pandemic and general tough trading conditions in the private hospital space, I believe its long term outlook is very positive. This could make it worth considering a long term and patient investment in its shares. Especially given the aforementioned tailwinds that the sector is experiencing. This is likely to lead to a strong increase in demand for its services over the next decade and beyond.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited and POLYNOVO FPO. The Motley Fool Australia has recommended Nanosonics Limited and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Happy couple enjoying ice cream in retirement.
Growth Shares

I'd buy these 2 ASX growth shares to secure an early retirement

These stocks are delivering growing dividends and rising profits.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Growth Shares

These beaten down ASX growth shares could rise 25% to 50%

Goldman Sachs thinks investors should buy these stocks while they are down in the dumps.

Read more »

A group of friends cheer around a smart phone.
Growth Shares

5 ASX growth shares rated as buys this month

Analysts have put buy ratings on these stocks. Let's see why they could be good options for growth investors.

Read more »

a man with a wide, eager smile on his face holds up three fingers.
Growth Shares

3 reasons this ASX growth stock is a top buy

Goldman Sachs thinks this stock could generate big returns.

Read more »

A man stands with arms crossed in front of a giant shadow of a body builder representing ASX small-cap stocks.
Growth Shares

3 of the best growth-focused ASX shares to buy in July

These ASX stocks look like potential market-beaters to me.

Read more »

happy investor, share price rise, increase, up
Growth Shares

These top ASX 200 growth shares could rise 20% to 45%

These growth stocks have been named as buys by brokers and tipped to rise strongly.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Growth Shares

5 ASX growth shares that could rise 10% to 40%

Brokers have put buy ratings on these stocks recently. Let's see what they are expecting from them.

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

5 top ASX growth shares that could rise ~10% to 25%

Analysts are tipping big returns from these growth stocks.

Read more »